Chiesi to buy Cornerstone Therapeutics for $9.50 a share


Italy's Chiesi Farmaceutic has agreed to acquire Cornerstone Therapeutics (CRTX) for $9.50 a share, below the latter's Friday close of $9.74, which gave it a market cap of $261.43M.

However, the price represents a premium of 78% over Cornerstone's closing price of $5.35 on February 15, 2013, the last trading day prior to an initial offer from Chiesi. It's also 42% above the high end of that bid.

Cornerstone CEO and Chairman Craig Collard, who owns 6% of the company, will use his shares to vote for the deal.

Cornerstone's shares have been suspended but are about to resume trading. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs